Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.